Preprint: Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine

Preprint: Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine

Preprint: Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine

The purpose of this study was to evaluate whether the bivalent COVID-19 vaccine protects against COVID-19.

Study does show that the increased number of doses were associated with a small but statistically significant increase risk of infection.

If you like this content and want more, I am doing a special lifetime membership offer. Click here:

Want to support this work?:
Buy me a coffee 🙂
Become my patron:

My substack:

#drbeen #koolbeens #COVID

This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

Flaws of this study:
Retrospective, cohort, study. Not
For me the study stops being usefule at the counting of cases instead of counting moderate to severe cases.
If the immune system was weakened then the participants should have more severe form of infection after each shot (not just more cases). But the study says: “There were too few severe illnesses for the study to be able to determine if the vaccine decreased severity of illness.”

Also counting a case without regard to the window of adaptive arm activation isn’t correct. For example 14 days from the vaccination. The bivalent vaccine was considered vaccinated based on 7 days after the vaccination – which seems OK to me.

Antibodies for sure wane. So, will cases occur, yes they will. Question is severe cases.
Every new dose will wane away. The only protection to test for is the severe cases. They admit that there were not many severe cases. I would have loved to see whatever number they had. It will be more clarifying than the cases. Also, the time since the vaccination (regardless of the number of doses) matters, not the number of doses.

Exposure types of the partcipants in the clinical settings will matter a lot for the outcomes. They have 50.6% clinical and 49.4% non-clinical cohort. They could only show the difference between these two but stated that they could not go deeper in the data due to the institutional limitations.

URL list from Tuesday, Jan. 10 2023

Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine | medRxiv

Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination | Science Immunology

Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis | Circulation

COVID vaccine study raises questions about boosters | Sandusky Register Vaccines save lives, but multiple boosters for COVID may not help, study suggests

COVID-19 Vaccine FAQs | Cleveland Clinic

Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States—October 25, 2020–February 26, 2022 – The Lancet Regional Health – Americas

Coronavirus (COVID-19) latest insights – Office for National Statistics

SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022 | MMWR

Frontiers | SARS-CoV-2 infections among asymptomatic individuals contributed to COVID-19 cases: A cross-sectional study among prospective air travelers from Ghana

Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis – PMC